Printer Friendly

FOREST LABORATORIES LICENSES ESTRADIOL TRANSDERMAL PATCH FROM ETHICAL PHARMACEUTICALS

 FOREST LABORATORIES LICENSES ESTRADIOL TRANSDERMAL PATCH
 FROM ETHICAL PHARMACEUTICALS
 NEW YORK, Aug. 12 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that it had licensed the U.S. rights to an estradiol transdermal patch developed by Ethical Pharmaceuticals from its parent company Ethical Holdings Ltd., the U.K.-based specialist pharmaceutical development group. Financial terms of the transaction were not disclosed. Forest is also negotiating for additional patch products under development by Ethical.
 Howard Solomon, president of Forest, stated: "The Ethical patch, which is about to be filed in Europe, should enter Phase III clinical trials in the United States in the near future. We believe this patch has certain advantages over Estraderm, the only patch currently approved in the U.S. The estradiol patch will fit well with our detailing of Monuril, an antibiotic used to treat urinary tract infections which we recently licensed from Zambon. We believe the market for estrogen replacement in postmenopausal hormone deficiency is growing rapidly and represents a significant market opportunity for Forest."
 -0- 8/12/92
 /CONTACT: Kenneth E. Goodman, VP-finance of Forest Laboratories, 212-421-7850/
 (FRX) CO: Forest Laboratories, Inc.; Ethical Pharmaceuticals ST: New York IN: MTC SU: LIC


CK-OS -- NY052 -- 6189 08/12/92 12:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 12, 1992
Words:211
Previous Article:CITY HOLDING COMPANY ANNOUNCES DIVIDEND
Next Article:MOODY'S RAISES RATING ON PENNSYLVANIA TURNPIKE COMMISSION'S TURNPIKE REVENUE BONDS TO 'A1'
Topics:


Related Articles
ETHICAL HOLDINGS PLC FISCAL 1993 YEAR END RESULTS
ETHICAL HOLDINGS PLC COMPLETES HORMONE REPLACEMENT THERAPY LICENSE AGREEMENT IN JAPAN
ETHICAL HOLDINGS PLC ANNOUNCES LAUNCH OF OESTROGEN PATCH IN THE UNITED KINGDOM
ETHICAL HOLDINGS PLC REPORTS FISCAL 1995 THIRD QUARTER RESULTS
ETHICAL HOLDINGS PLC APPOINTS GROUP PRESIDENT OF NORTH AMERICAN OPERATIONS
Solvay Pharmaceuticals, Inc. Acquires Marketing Rights For Innovative Combination Hormone Replacement Patch
Watson Reacquires Rights From Procter & Gamble for Female Hormone Replacement Therapy Products.
Permatec Announces a Licensing and Development Agreement With Biosante Pharmaceuticals, Inc.
Antares Pharma's Licensee, BioSante Pharmaceuticals, Inc., Sub-Licenses Rights to Hormone Product to Solvay Pharmaceuticals B.V.
Noven and Endo announce licensing agreement for fentanyl patch.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters